XDH and hyperuricemia: Accordingly, several clinical and epidemiological data by us and other researchers have demonstrated the relationship between hyperuricemia and cardiometabolic risk and disease, thereby overwhelming the beneficial actions of UA and suggesting UA as a potential pharmacological target (e.g., xanthine oxidase inhibitors) in cardiometabolic patients, especially in those with hyperuricemia [2,3,13,14,15,16,17].